Foresight Capital's model of investing across early, middle, and late stages from one fund provides a unique advantage. Their understanding of late-stage market needs and challenges directly informs and improves their selection process for early-stage companies, creating a powerful feedback loop that specialized VCs lack.
Instead of passively waiting for pitches, proactive VCs like Foresight Capital build new companies by acquiring promising assets. They actively source clinical or later-stage assets, particularly from Asia where market dynamics are favorable, and then build a new company around them with a proven entrepreneur from their network.
A biotech boom in China, fueled by returning scientists and VC funding, hit a wall when public market access was restricted. This liquidity crunch left many high-quality companies with promising assets undervalued and in need of capital, creating a prime investment window for savvy foreign investors to acquire technology.
Despite geopolitical tensions, the US and Chinese biotech industries are highly synergistic. An estimated 80% of US biotech companies use Chinese Contract Research Organizations (CROs) for cheaper and faster R&D. This on-the-ground reality shows a reliance on international partners for core development activities, enabling a more efficient global ecosystem.
A primary strategy for early-stage investment is partnering with entrepreneurs with a successful track record, often from previous portfolio companies. VCs will back a person they trust, like a former Chief Scientific Officer or a repeat founder, valuing proven execution experience sometimes even more than a nascent scientific concept.
Unlike a research scientist who focuses deeply on a single project, a biotech investor's work involves constant topic rotation. Their value comes from looking broadly across therapeutic areas and company stages, speaking with up to 10 companies a day to identify patterns and opportunities in a rapidly changing sector.